| Recombinant Macrophage Targeted Enzyme Replacement Therapy for Gaucher Disease in India. | |
| | |
MedLine Citation:
|
PMID: 22080680 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: Gaucher disease in India has been reported only in a few case reports from India. The aim of the study was to assess the response to enzyme replacement therapy in Indian patients with Gaucher disease. DESIGN: Retrospective analysis of patients receiving CHO-derived recombinant macrophage-targetted glucocorebrosidase. SETTING: Five centers from India with experience in treating lysosomal storage disorders. PATIENTS: The diagnosis of Gaucher disease was confirmed by low glucocerebrosidase levels, though it was first made on splenectomy in 8 and on bone marrow examination in 9 patients. Twenty five of 52 patients diagnosed with Gaucher disease (17 Type I, 8 mild Type III) received treatment for >6 months. Indications for treatment included symptomatic anemia, thrombo-cytopenia, organomegaly, bone disease or mild neurological symptoms leading to impairment of quality of life. Patients with significant neurological involvement were excluded. The drug infusions were given intravenously every 15 days. MAIN OUTCOME MEASURES: Hemoglobin, platelet counts, liver and spleen volumes and growth parameters. RESULTS: 22 of the 25 children who survived were analyzed. After 6 months of treatment, the mean (range) increase in hemoglobin was 1.5 (-3.4 to 6.1) g/dL (P=0.01) and in platelet count was 32 x 109/L (-98.5 x 109 to 145.5 x109) /L (P=0.02). The mean (range) increase in weight was 3 kg (-5.6 to 10.5) (P=0.04) and in height was 7.1 cm (0 to 26.5) (P=0.0003). Liver size decreased by a mean (range) of 38.5% (- 5.5 to 86.7) (P=0.0003) and the spleen size by 34.8% (0 to 91.7) (P=0.004). All patients had improvement in bone pains and in 2 patients, neurological symptoms improved with others remaining static. CONCLUSIONS: This is the first reported cohort of patients in India reporting our experience with imiglucerase enzyme replacement therapy for treatment of Gaucher Disease in India. |
| | |
Authors:
|
A Nagral; P Mewawalla; S Jagadeesh; M Kabra; S R Phadke; I C Verma; R D Puri; N Gupta; P S Kishnani; P K Mistry |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Indian pediatrics Volume: 48 ISSN: 0974-7559 ISO Abbreviation: - Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-11-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985062R Medline TA: Indian Pediatr Country: - |
Other Details:
|
Languages: ENG Pagination: 779-784 Citation Subset: - |
Affiliation:
|
Department of Gastroenterology, Jaslok Hospital and Research Centre, Mumbai, India; #Department of Genetics, Mediscan systems, Chennai, India; ?Division of Clinical Genetics, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India; $Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical sciences, Lucknow, India;#Centre for Genetic Medicine, Sir Ganga Ram Hospital, New Delhi, India; ##Division of Medical Genetics, Duke University Medical Center, Durham, USA; and **Section of Pediatric Hepatology and Liver Transplantation; Yale University School of Medicine, New Haven, USA. Correspondence to: Dr. Aabha Nagral, 7, Snehasagar, Prabhanagar, Prabhadevi, Mumbai 400 025, India. aabhanagral@gmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lessons from Genetically Altered Mesenchymal Stem Cells (MSCs); Candidates for Improved MSC-Directed...
Next Document: Gauchers disease presenting with portal hypertension.